LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・AbCellera Biologics Inc

AbCellera Biologics Inc

Suletud

SektorTervishoid

4.09 -6.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.07

Max

4.12

Põhinäitajad
By Trading Economics
Sissetulek	-34M -43M
Müük	-37M 8.3M
Kasumimarginaal	-519.122
Töötajad	562
EBITDA	-24M -43M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+113.94% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	696M 1.6B
Eelmine avamishind	10.71
Eelmine sulgemishind	4.09

Uudiste sentiment

By Acuity

37%

63%

88 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. mai 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17. mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17. mai 2026, 23:07 UTC

Omandamised, ülevõtmised, äriostud

UOB: Transactions Part of Group's Capital Reallocation Strategy

17. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

UOB: Share Sale Agreements Entered With Singland Properties

17. mai 2026, 23:05 UTC

Omandamised, ülevõtmised, äriostud

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Fund Stake Acquisition via Internal Resources

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire Stake for $389 Million

17. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16. mai 2026, 16:27 UTC

Omandamised, ülevõtmised, äriostud

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. mai 2026, 15:26 UTC

Omandamised, ülevõtmised, äriostud

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16. mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

113.94% tõus

12 kuu keskmine prognoos

Keskmine 8.75 USD 113.94%

Kõrge 13 USD

Madal 7 USD

Põhineb 6 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

88 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.